NCT00117429View on ClinicalTrials.gov

Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART)

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

September 30, 2007

Study Completion Date

January 31, 2010

Conditions
HIV Infections
Interventions
BIOLOGICAL

HIV gp120/NefTat/AS02A Vaccine

im injection, 0.6-0.7 ml

Trial Locations (1)

02114

Massacusetts General Hospital -Infectious Disease Unit, Boston

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Marcus Altfeld, M.D., Ph.D.

INDIV